Table 1 Association of TC2N expression with BC clinicopathological characteristics
From: Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer
Variable | Category | Relative TC2N expression | P | |
|---|---|---|---|---|
High (n = 32) | Low (n = 43) | |||
Age (years) | <45 | 17 | 21 | 0.713 |
≥45 | 15 | 22 | ||
Clinical stage (AJCC) | I-II | 27 | 19 | <0.001 |
III | 5 | 24 | ||
Histological grade | 1 | 2 | 11 | 0.091 |
2 | 24 | 26 | ||
3 | 6 | 6 | ||
Depth of tumor invasion | T1-2 | 18 | 31 | 0.154 |
T3-4 | 14 | 12 | ||
Lymph node metastasis | N 0 | 27 | 19 | <0.001 |
N 1-3 | 5 | 24 | ||
Tumor size | <5 cm | 10 | 25 | 0.021 |
≥5cm | 22 | 18 | ||
PR | Positive | 15 | 23 | 0.572 |
Negative | 13 | 15 | ||
ER | Positive | 17 | 26 | 0.516 |
Negative | 11 | 12 | ||
HER-2 | Positive | 27 | 27 | 0.039 |
Negative | 5 | 16 | ||
